Weight-loss medicines: Biocon eyes a $100 billion jackpot with weighty pivot
Weight-loss drugs: Biocon Ltd. is shifting focus to anti-obesity therapies as patents for key medications expire, leading to a surge in generic supply. The Bengaluru-based company secured UK approval for the first generic version of liraglutide injectible, positioning itself as a leader in this evolving market. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 8, 2024 Category: Pharmaceuticals Source Type: news
Roche and Alnylam present positive results from the Phase II KARDIA-2 study of zilebesiran added to standard of care antihypertensives in patients with inadequately controlled hypertension
The KARDIA-2 study met its primary endpoint demonstrating additive, placebo-adjusted systolic blood pressure reductions of up to 12.1 mmHgat month three. These results were statistically significant and clinically meaningfulZilebesiran demonstrated an encouraging safety and tolerability profile when added to standard of care antihypertensives Basel, 7 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam today released detailed results from the Phase II KARDIA-2 study evaluating the efficacy and safety of a single subcutaneous dose of zilebesiran when added to one of three standard of care (SOC) antihypertensives. T...
Source: Roche Investor Update - April 7, 2024 Category: Pharmaceuticals Source Type: news
Sanofi looks for accelerated growth in India; plans fast-tracking of product pipeline
Sanofi, a leading French pharmaceutical company, aims to expand its presence in the Indian market by introducing new drugs, enhancing localization efforts, and collaborating with domestic firms. Managing Director Rodolfo Hrosz highlights the significant growth potential in India and emphasizes the company's focus on addressing the diabetes segment. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 7, 2024 Category: Pharmaceuticals Source Type: news
Legend Biotech's CARVYKTI ® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line…
(Source: Reuters: Health)
Source: Reuters: Health - April 6, 2024 Category: Consumer Health News Source Type: news
Biotech Executive Who Bet on Rival's Stock Committed Insider Trading, Jury Says
The SEC wins ‘shadow trading’ case, extending the application of the law. (Source: Reuters: Health)
Source: Reuters: Health - April 6, 2024 Category: Consumer Health News Source Type: news
U.S. FDA Approves Expanded Use Of J & J's Cancer Cell Therapy U.S. FDA Approves Expanded Use Of J & J's Cancer Cell Therapy
The U.S. Food and Drug Administration on Friday allowed the expanded use of Johnson& Johnson and Legend Biotech ' s Carvykti cell therapy as an earlier treatment for...Reuters Health Information (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 6, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Former St. Vincent Charity medical building in Cleveland is sold for $1.9 million
The medical office building across the street from the former St. Vincent Charity Medical Center in Cleveland's Central neighborhood has been sold. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 6, 2024 Category: Biotechnology Authors: Mary Vanac Source Type: news
Scispot Joins Ontario Genomics' BioCreate Program to Enhance Ontario's Role on the Global Biomanufacturing Stage
Ontario Genomics Awards Grant and Business Support to Scispot in a Highly Competitive Selection KITCHENER, ON, April 5, 2024 /PRNewswire-PRWeb/ -- Scispot, the leading tech stack for biotech, announced its selection into the BioCreate Program by Ontario Genomics. This selection... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 5, 2024 Category: Pharmaceuticals Tags: AWD Source Type: news
OCGN Stock Alert: Why Is Ocugen Up 20% Today?
Biotechnology firm Ocugen (NASDAQ:OCGN) — which specializes in developing gene therapies to address blindness diseases — saw its shares move higher on an encouraging clinical development. An advisory committee responsible for overseeing safety matters approved Ocugen to use a medium dosage of its…#ocugen #dsmb #peterchang #dsmbchair #ocgn #amd #joshenomoto (Source: Reuters: Health)
Source: Reuters: Health - April 5, 2024 Category: Consumer Health News Source Type: news
South Jersey medical school appoints longtime educator as permanent dean
After nearly three decades at the South Jersey medical school, the educator and researcher will assume the dean role on a permanent basis. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 5, 2024 Category: Biotechnology Authors: John George Source Type: news
Form D Friday: 'AI Proteins' startup raises $5M to do exactly what its name suggests
Form D Friday is a Boston Business Journal feature highlighting regulatory filings from Boston-area companies raising capital for new projects or expanding their businesses. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 5, 2024 Category: Biotechnology Authors: Lucia Maffei Source Type: news
Latinx Business Leadership Awards: Individual honoree Carlos Bohorquez of El Camino Health
Finance head puts patients first at area hospital. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 5, 2024 Category: Biotechnology Authors: Danny King Source Type: news
Central Florida Health Maintenance Organizations
Rank
Insurer
2023 total C. Fla. enrollment
Brevard County
Lake County
Orange County
Osceola County
S (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 5, 2024 Category: Biotechnology Source Type: news
Netsmart, Serviam partner to extend benefits of value-based care to senior-living facilities
Both companies aim to position themselves for the growth of value-based care. Doing it with a local partner is a bonus. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 5, 2024 Category: Biotechnology Authors: Grace Mayer Source Type: news
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024
PITTSBURGH, April 05, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. LIPO ("Lipella," "our", "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces that its abstract has been accepted for the 2024 American…#pittsburgh #lipella #illinois #jonathankaufman #lp50 #nmibc #asco (Source: Reuters: Health)
Source: Reuters: Health - April 5, 2024 Category: Consumer Health News Source Type: news
